Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

“Chronic Kidney Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Kidney Disease Market.

The Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Kidney Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Kidney Disease treatment therapies with a considerable amount of success over the years. Chronic Kidney Disease Key players such as – Aria Pharmaceuticals, Unicycive Therapeutics, Ionis Pharmaceuticals, Pharmicell, Kibow Biotech, AstraZeneca, Bayer, Prokidney, Novo Nordisk, KBP Biosciences, and others, are developing therapies for the Chronic Kidney Disease treatment 
• Chronic Kidney Disease Emerging therapies such as – TXR-1208, UNI-494, ION532, Cellgram-CKD, US-APR2020, Zibotentan+Dapagliflozin, Runcaciguat, Renal Autologous Cell Therapy, Ziltivekimab, KBP-5074, and others are expected to have a significant impact on the Chronic Kidney Disease market in the coming years.   
• In November 2021, KBP Biosciences initiated a Phase III, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal to evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] ≥15 to ≤44 mL/min/1.73 m^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and

Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Chronic Kidney Disease Pipeline Therapeutics Assessment

• Chronic Kidney Disease Assessment by Product Type
• Chronic Kidney Disease By Stage and Product Type
• Chronic Kidney Disease Assessment by Route of Administration
• Chronic Kidney Disease By Stage and Route of Administration
• Chronic Kidney Disease Assessment by Molecule Type
• Chronic Kidney Disease by Stage and Molecule Type

DelveInsight’s Chronic Kidney Disease Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Chronic Kidney Disease Therapeutics Market include:

Key Companie developing therapies for the Chronic Kidney Disease treatment are – Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, KBP Biosciences Co., Ltd., and others

Emerging Chronic Kidney Disease Drugs Under Different Phases of Clinical Development Include:

• TXR-1208: Aria Pharmaceuticals
• UNI-494: Unicycive Therapeutics
• ION532: Ionis Pharmaceuticals
• Cellgram-CKD: Pharmicell
• US-APR2020: Kibow Biotech
• Zibotentan+Dapagliflozin: AstraZeneca
• Runcaciguat: Bayer
• Renal Autologous Cell Therapy: Prokidney
• Ziltivekimab: Novo Nordisk
• KBP-5074: KBP Biosciences

Get a Free Sample PDF Report to know more about Chronic Kidney Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

Chronic Kidney Disease Pipeline Analysis:

The Chronic Kidney Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.
• Chronic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Chronic Kidney Disease product details are provided in the report. Download the Chronic Kidney Disease pipeline report to learn more about the emerging Chronic Kidney Disease therapies

Chronic Kidney Disease Pipeline Market Drivers

• Increasing prevalence of Chronic Kidney Disease
•  Increasing R&D activities

Chronic Kidney Disease Pipeline Market Barriers

• Increased risk of associated comorbidities
• Limited patient awareness about the disease
• Poor Patient Compliance

Scope of Chronic Kidney Disease Pipeline Drug Insight    

• Coverage: Global
• Key Chronic Kidney Disease Companies: Aria Pharmaceuticals, Unicycive Therapeutics, Ionis Pharmaceuticals, Pharmicell, Kibow Biotech, AstraZeneca, Bayer, Prokidney, Novo Nordisk, KBP Biosciences, and others
• Key Chronic Kidney Disease Therapies: TXR-1208, UNI-494, ION532, Cellgram-CKD, US-APR2020, Zibotentan+Dapagliflozin, Runcaciguat, Renal Autologous Cell Therapy, Ziltivekimab, KBP-5074, and others
• Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers 

Request for Sample PDF Report for Chronic Kidney Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Chronic Kidney Disease drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com